Join to View Full Profile
1400 S Orange AveOrlando, FL 32806
Dr. Thomas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sajeve Thomas is an oncology specialist based in Orlando, FL, with subspecialties in melanoma, sarcoma and gastrointestinal cancers. Dr. Thomas completed medical education in 2005 at the University of Florida College of Medicine and underwent residency in internal medicine at the University of South Florida Morsani, followed by a hematology and medical oncology fellowship at the University of Florida. Currently, Dr. Thomas serves as the Director of Cutaneous/Connective Malignancies and Section Lead for Solid Tumor Cellular Therapy at Advent Health Cancer Institute. Dr. Thomas has extensive experience in melanoma, skin cancers, merkel cell, mycoisis fungoides, neuroendocrine tumors, soft tissue sarcomas, bone sarcomas, and gastrointestinal malignancies. Notable publications include works on lifileucel tumor-infiltrating lymphocyte cell therapy and partnerships in various clinical trials.
Education & Training
University of FloridaFellowship, Hematology and Medical Oncology, 2008 - 2011
University of South Florida MorsaniResidency, Internal Medicine, 2005 - 2008- University of Florida College of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2007 - 2028
WV State Medical License 2025 - 2027
MT State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts FollowMyHealth, Allscripts, 2014, 2017
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2014, 2017
- CMS Meaningful Use Stage 1 Certification Sunrise Acute Care, Allscripts, 2014, 2017
Clinical Trials
- Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
- Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Start of enrollment: 2012 Dec 17
- FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 16 citationsLong-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.Theresa Medina, Jason A Chesney, Harriet M Kluger, Omid Hamid, Eric D Whitman
Journal of Clinical Oncology. 2025-11-20 - 4 citationsLifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhib...Harriet Kluger, Götz Ulrich Grigoleit, Sajeve Thomas, Evidio Domingo-Musibay, Jason A Chesney
Cancer Communications. 2025-10-01 - A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carc...Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z Win
Cancer Communications. 2025-08-01
Press Mentions
Cancer Specialists in Florida See Dramatic Results with New Clinical TrialNovember 22nd, 2021
Iovance: Assessing the Potential for Further UpsideMay 20th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
